Contrary to simply stopping tumor growth, the biomedical engineers at Duke University have successfully demonstrated a new treatment for pancreatic cancer in a mouse model that may make a…
Medscape Medical News reports that results have been received from the OCCLURANDOM Phase 2 trial which is the first randomized trial investigating the antitumor effect of the peptide receptor radionuclide…
Are there therapeutic options for patients living with unresectable (inoperable) pancreatic cancer? According to an article in MedScape, researchers sought to understand whether sunitinib or a combination of peptide receptor…
In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to prevent, diagnose, or treat rare conditions. These are conditions affecting fewer than 200,000 Americans.…
The Orphan Drug Act of 1983 was designed to facilitate the development of orphan drugs, or drugs designed for patients with rare or life-threatening conditions. Now, the FDA grants…
Dr. Jung-Mo Ahn, associate professor at Dallas University in Texas, created a molecule that kills a broad range of treatment-resistant cancers. The newly targeted group includes triple-negative breast cancer.…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
In recent years, there have been advances in the treatment of pancreatic cancer. This is crucial, as the prognosis for this cancer is often poor, and the cancer itself is…
Pancreatic cancer is one of the deadliest forms of cancer. According to the American Cancer Society (ACS), only about 11% of patients are expected to survive more than five years…
The FDA has just provided AB001 the Orphan Drug designation for both acute myeloid leukemia (AML) and pancreatic cancer. This small molecule was developed by Vopec Pharmaceuticals and Agastiya Biotech.…
In Detroit, activists recently came together to raise money for pancreatic cancer research through a walk called “The PanCAN PurpleStride walk.” Each year about 62,000 people are newly diagnosed with pancreatic…
Those who are at high risk for pancreatic cancer now have a new screening option thanks to a novel program developed by Hackensack University Medical Center. The Center has launched…
SOTIO Biotech has just announced that the first patient has received the first dose of treatment in their Phase 1/2 trial for SOT102. SOT102 is an investigative treatment for pancreatic…
Pancreatic cancer is typically a difficult cancer to treat, leading to poor outcomes and high mortality rates. One of the reasons for this is the difficulty of diagnosis; it often…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Unfortunately, a pancreatic cancer diagnosis also comes with a poor prognosis. Since many people do not receive a diagnosis until later stages of the cancer, the 5-year survival rate is…
Pancreatic cancer can present numerous problems for medical professionals. To start, this cancer can be difficult to detect and diagnose in early stages. By the time pancreatic cancer progresses,…
Pancreatic cancer so far has been able to escape early detection. When it is discovered, it is usually in an advanced stage and difficult to treat. According to a…
The Tokyo University of Science recently published a report stating that its team of scientists was successful in developing a polymer-based-hydrogel, a welcomed improvement to the complicated formulations currently in…
Years ago, talabostat (BXCL701) failed during a Phase 3 clinical trial to evaluate the therapy for patients with pancreatic cancer. However, drug developer BioXcel Therapeutics (“BioXcel”) did not give up…
According to Healio, the FDA recently granted Orphan Drug designation to nadunolimab (CAN04), a treatment candidate for patients with pancreatic cancer. Orphan Drug designation is given to drugs or biologics…
On August 11, 2021, biopharmaceutical company Lantern Pharma, Inc. ("Lantern") shared the news that its small molecule drug candidate, LP-184 (hydroxyureamethylacylfulvene), received Orphan Drug designation from the FDA. This status…
On July 28, 2021, biopharmaceutical company Thetis Pharmaceuticals ("Thetis") shared that its small molecule Resolvin E1 (RvE1) therapy, TP-317, received Orphan Drug designation from the FDA. While TP-317 has…
The symptoms of terminal pancreatic cancer are subtle. The disease is usually not diagnosed until it has substantially progressed, leaving a dismal five-year overall survival of five to ten percent.…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
